Carcinoma of the Rectum - Management

Background

Clinical Presentation & Diagnosis

• Most common symptom: Change in bowel habits
• Other features: rectal bleeding, iron deficiency anemia, change in stool caliber, tenesmus (late, suggests invasion), palpable rectal mass
• Diagnosis: Biopsy at endoscopy; complete colonoscopy preferred (3-5% synchronous tumor risk)
• Tumour marker: CEA - not diagnostic but used for prognosis and post-treatment surveillance
• DRE: Assess distance from anal verge, fixity, and sphincter involvement
• Rigid proctoscopy is preferred over flexible endoscopy for measuring distance from anal verge

Staging Workup

• MRI pelvis (preferred): high-resolution T2-weighted thin-cut sequences for depth of invasion, nodal status, and circumferential resection margin (CRM)
• Endorectal ultrasound (EUS): historically used, now limited due to operator-dependency and poor accuracy with bulky/posterior tumors
• Threatened CRM = tumor within 1 mm on MRI - highly predictive of positive radial margin, poor disease-free and overall survival

• CT chest and abdomen (standard)
• MRI abdomen if liver metastasis concern
• PET: not standard; considered for non-diagnostic CT or to confirm solitary metastasis

Risk Stratification - "The Good, the Bad, and the Ugly"

Neoadjuvant Therapy

Long-Course Chemoradiotherapy (LCRT)

• 45-50 Gy in 25 fractions (1.8-2 Gy/day) + concurrent fluoropyrimidine (5-FU or capecitabine)
• Surgery after 6-10 weeks (8 weeks preferred) - longer delay increases pathologic complete response (pCR) rate
• Standard for high-risk/bulky locally advanced rectal cancer (LARC)

Short-Course Radiotherapy (SCRT)

• 5 Gy x 5 fractions over 5 days
• Surgery within 7-10 days OR delayed 5-12 weeks (delayed preferred - lower complication rate)
• Non-inferior to LCRT for local recurrence, DFS, and OS with less toxicity and lower cost (Polish trial, Trans-Tasman trial)
• Increasingly used in the US; widely used in Europe

Total Neoadjuvant Therapy (TNT) - Current Practice Shift

• Goal: Deliver ALL preoperative systemic therapy + RT before surgery to address micrometastatic disease early
• Radiation given in short or long-course format
• Chemotherapy (FOLFOX) given as induction (before RT) or consolidation (after RT)
• Results in higher pCR rates vs CRT alone; better treatment completion
• NCCN indications for TNT: T4 lesions, T3 with threatened margins, medically inoperable patients; can also consider for T3 without threatened margins and T1-T2 N+ disease
• Early data suggest improved survival vs conventional CRT + surgery + adjuvant chemo

2024 ASCO Guideline (PMID: 39116386) is the most recent evidence-based guideline on management of locally advanced rectal cancer, published in J Clin Oncol Oct 2024 - may update some older textbook recommendations above.

Surgical Management

Core Principle: Total Mesorectal Excision (TME)

1. Complete - intact mesorectal fascia
2. Near-complete - small defects <5 mm
3. Incomplete - defects >1 cm or muscularis propria exposed

Preoperative Preparation

• Mechanical bowel preparation + oral antibiotics (reduces SSI compared with MBP alone)
• Stoma site marking if planned
• DVT prophylaxis and IV antibiotics on day of surgery

Surgical Procedures by Location

Sphincter Preservation

• Attempted whenever adequate distal margin is achievable with functional sphincter
• 1 cm distal margin acceptable for low tumors if complete TME is done
• Neoadjuvant therapy may downsize tumor to allow LAR instead of APR (though not strongly guideline-supported for T2 N0 disease)

Surgical Approach

• Open vs. laparoscopic vs. robotic - no definitive difference in oncologic outcomes
• Laparoscopic: less pain, lower ileus, shorter stay, less blood loss
• Robotic: lower conversion rate, better 3D visualization, instrument articulation; but longer operative times and higher cost
• Transanal TME (taTME): emerging technique for low rectal cancers, particularly in obese patients or narrow pelvis

Stage-Specific Management Summary

Stage IV / Synchronous Metastatic Disease

• Assess resectability in multidisciplinary setting (including hepatic/thoracic surgeons)
• Resectable = margin-negative removal of all known tumor possible with adequate organ reserve
• No benefit from incomplete R1/R2 resection in asymptomatic patients - systemic chemotherapy preferred
• For resectable liver disease: 3-4 months systemic therapy first (assess biology, facilitate resectability), then surgical options:
  • Combined (simultaneous primary + liver resection): healthy patients, upper rectal tumors, minor hepatic resections
  • Rectum-first approach
  • Liver-first approach: if large liver burden, threatened CRM, short-course RT before liver surgery

Watch-and-Wait (Nonoperative Management)

• Surveillance protocol without surgery
• Local tumor regrowth may occur - requires TME surgery
• Particularly appealing for distal rectal cancer where APR with permanent stoma would otherwise be required
• Currently supported by retrospective data; considered experimental pending prospective trial maturation
• Evidence basis: International Watch & Wait Database (IWWD)

Immunotherapy (dMMR/MSI-H tumors)

• Checkpoint inhibitors are first-line for stage IV dMMR/MSI-H colorectal cancer
• dMMR is rare in rectal cancer (~3-7%; most dMMR tumors arise in right colon)
• Neoadjuvant PD-1 blockade in dMMR LARC: early data show 100% cCR rate (12-patient prospective study), avoiding CRT or surgery entirely
• Long-term durability data pending; likely to change paradigms for dMMR LARC

Adjuvant Therapy

• Adjuvant chemotherapy (typically FOLFOX or CAPOX) after surgery for Stage III and high-risk Stage II
• If TNT approach was used preoperatively, adjuvant chemotherapy schedule is incorporated into the TNT protocol itself
• Adjuvant radiation is rarely given if adequate neoadjuvant radiation was delivered

Surveillance After Curative Resection

• Colonoscopy 3-6 months post-resection (if not completed before surgery)
• CEA monitoring
• CT chest/abdomen/pelvis - at regular intervals per NCCN guidelines
• MRI pelvis for local recurrence assessment

• Current Surgical Therapy 14e - "Management of Rectal Cancer" (Low & Mutch)
• Sabiston Textbook of Surgery - "Management of Rectal Cancer with Synchronous Metastases"
• Mulholland & Greenfield's Surgery 7e - Watch and Wait; Risk Stratification Algorithm
• 2024 ASCO Guideline on Locally Advanced Rectal Cancer: Scott AJ et al., J Clin Oncol Oct 2024 - PMID 39116386